Co-Authors
This is a "connection" page, showing publications co-authored by MANDEEP BAJAJ and YOCHAI BIRNBAUM.
Connection Strength
3.156
-
Type 2 diabetes and cardiovascular disease: A metabolic overview of recent clinical trials. J Diabetes Complications. 2017 02; 31(2):291-294.
Score: 0.592
-
PTEN upregulation may explain the development of insulin resistance and type 2 diabetes with high dose statins. Cardiovasc Drugs Ther. 2014 Oct; 28(5):447-57.
Score: 0.516
-
Myocardial protection against ischemia-reperfusion injury by GLP-1: molecular mechanisms. Metab Syndr Relat Disord. 2012 Dec; 10(6):387-90.
Score: 0.448
-
DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome. Basic Res Cardiol. 2019 08 06; 114(5):35.
Score: 0.180
-
Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation. Cardiovasc Drugs Ther. 2018 12; 32(6):553-558.
Score: 0.172
-
SGLT2 Inhibitors and Cardiovascular Outcomes: Current Perspectives and Future Potentials. Curr Diab Rep. 2018 07 11; 18(9):63.
Score: 0.168
-
Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes. Cardiovasc Drugs Ther. 2018 04; 32(2):135-145.
Score: 0.164
-
GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials. Cardiovasc Drugs Ther. 2018 02; 32(1):65-72.
Score: 0.163
-
Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome. BMJ Open Diabetes Res Care. 2016; 4(1):e000227.
Score: 0.147
-
Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus. Cardiovasc Drugs Ther. 2012 Dec; 26(6):445-56.
Score: 0.114
-
Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes. Am J Physiol Heart Circ Physiol. 2013 Jan 01; 304(1):H131-41.
Score: 0.113
-
The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes. Atherosclerosis. 2012 Jul; 223(1):204-8.
Score: 0.109
-
SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes. Cardiovasc Drugs Ther. 2022 12; 36(6):1091-1108.
Score: 0.052
-
Acupuncture Reduces Hypertrophy and Cardiac Fibrosis, and Improves Heart Function in Mice with Diabetic Cardiomyopathy. Cardiovasc Drugs Ther. 2020 12; 34(6):835-848.
Score: 0.048
-
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther. 2017 Apr; 31(2):119-132.
Score: 0.038
-
Aleglitazar, a dual peroxisome proliferator-activated receptor-a and -? agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia. Diab Vasc Dis Res. 2017 03; 14(2):152-162.
Score: 0.038
-
Aleglitazar, a Balanced Dual PPARa and -? Agonist, Protects the Heart Against Ischemia-Reperfusion Injury. Cardiovasc Drugs Ther. 2016 Apr; 30(2):129-41.
Score: 0.036
-
MicroRNA-dependent cross-talk between VEGF and HIF1a in the diabetic retina. Cell Signal. 2013 Dec; 25(12):2840-7.
Score: 0.030
-
Dickkopf-1 (DKK1) phosphatase and tensin homolog on chromosome 10 (PTEN) crosstalk via microRNA interference in the diabetic heart. Basic Res Cardiol. 2013 May; 108(3):352.
Score: 0.029